reviews glp-1 receptor agonists were originally developed to treat people with type 2 diabetes. More recently, GLP-1 drugs have been trialled in people with obesity. Three Cochrane have found that three drugs ( use oral spray November in review: GLP-1 breakthroughs,

The Growing Role of GLP-1s in Employer and Health System Weight Management Strategies Obesity continues to drive higher healthcare costs, reduced productivity, and chronic disease burdensimpacting both employers and health systems

only two of our predicted recoveries died and three of our predicted deaths survived

Semaglutide is not detected on standard pre-employment drug panels, which use immunoassay technology targeting controlled substances like opioids, amphetamines, cannabis metabolites, cocaine, and benzodiazepines

Other serious side effects can include increased blood pressure and heart rate, seizures (especially in patients with risk factors), and allergic reactions